Payton Richards·Apr 3, 2025Root-Cause Innovation: Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) Redefines Cardiac CareHeart disease is complex — but Cardiol Therapeutics is making it clearer and more treatable by going straight to the source. Their…
Payton Richards·Apr 3, 2025From Bench to Bedside: Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) CardiolRx™ Pushes Toward…Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is making strides in the treatment of inflammation-driven cardiovascular disease. Its lead…
Payton Richards·Apr 3, 2025Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL) Is Building the Future of Inflammation-Focused…As the medical community deepens its understanding of the inflammatory origins of heart disease, Cardiol Therapeutics is positioning itself…
Payton Richards·Mar 26, 2025Targeting Inflammation to Transform Cardiac Care: Inside Cardiol Therapeutics (NASDAQ: CRDL | TSX…Cardiovascular disease remains one of the most difficult areas of medicine to innovate in — especially when it comes to…
Payton Richards·Mar 26, 2025Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) CEO Shares Vision for CardiolRx™ as Phase III Trial…David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL), recently joined PRISM MarketView to discuss the…
Payton Richards·Mar 26, 2025Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): Advancing Through Clinical Trials for FDA ApprovalCardiol Therapeutics is progressing rapidly through clinical trials to bring CardiolRx™ to market, a potential first-in-class treatment for…
Payton Richards·Mar 19, 2025Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): Pushing the Boundaries of Heart HealthCardiol Therapeutics is setting new standards in cardiovascular medicine with groundbreaking research and cutting-edge therapies. Their…
Payton Richards·Mar 19, 2025Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): Strategic Engagements and Clinical AdvancementsCardiol Therapeutics Inc., a clinical-stage life sciences company, continues to drive innovation in anti-inflammatory and anti-fibrotic…
Payton Richards·Mar 19, 2025Cardiol Therapeutics Inc.The AGM will focus on Cardiol’s recent scientific developments, financial stability, and long-term business strategies to enhance…
Payton Richards·Mar 14, 2025Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL): A Long-Term Investment in the Future of…Positioned for Sustained Growth in the Biotech Sector
